Amgen to Highlight 19 Abstracts on Osteoporosis Disease State and Treatment at American Society for Bone and Mineral Research Annual Meeting

Results From Phase 3 FRAME Study of Romosozumab Evaluate Fracture Risk Reduction in Women With Postmenopausal Osteoporosis Real-World and Clinical Data Focus on Long-Term Efficacy and Safety of Prolia® (Denosumab), Provide Insights on Therapy Compliance in Patients With Postmenopausal Osteoporosis

Amgen - Investors - RSS Content